OUP Webinar : Small Molecule vs Antibody Development Challenges

Therapeutics remain the primary focus for life science venture investments. As we all know, pre-clinical development of therapeutics is complicated, time consuming, and capital intensive. In the early stages of development, multiple aspects of a therapeutic product need to be optimized to enhance its drug-like properties. However, given the limited time and resources in the academic setting, what aspects of development should inventors focus on? Before diving into drug development, inventors should ask themselves: What is feasible in an academic setting? What is valued more by the investors? Should it be performed in-house or be out-sourced? How much would it cost?
This webinar the challenges facing small molecule and antibody development with Joseph Vacca, chemistry consultant for numerous start-ups developing small molecule therapeutics, and Steve Holmes, CEO of Capella Biosciences, an OUP portfolio company developing several antibody products. We start with a high-level discussion on the overall development process and its key challenges followed by a conversation and Q&A around the areas where researchers should focus to extract the most value from their asset.